Treatment with apremilast led to significantly improvedpatient-reported quality of life (QoL) outcomes in patients with moderate-to-severe plaque psoriasis of the scalp, according to the STYLE* study presented at EADV 2020.
Subjective cognitive decline (SCD) or anxiety symptoms in older individuals are independently associated with an increased risk of mild cognitive impairment (MCI) or dementia, a recent study has shown.
High-sensitivity cardiac troponin I (hs-cTnI) is a better marker of cardiovascular disease (CVD) risk in elderly adults than hs-cTnT and improves risk stratification in this population, a recent study has found.
Distribution of body fat can affect a person’s risk of coronary heart disease (CHD), suggests a study presented at the AASLD 2020 Liver Meeting, which shows that people with high abdominal fat but low liver fat have an increased risk of CHD events than those with other fat distribution.
Crushing prasugrel tablets and administering it as a powder to patients with ST-segment elevation myocardial infarction (STEMI) prior to percutaneous coronary intervention (PCI) enhances the potency of platelet inhibition but fails to improve early coronary reperfusion, as shown in the results of the COMPARE CRUSH trial.
Fetoscopic laser ablation (FLP) is an effective treatment for twin-to-twin transfusion syndrome (TTTS) in monochorionic twin pregnancies, but it requires a tertiary neonatal facility and a highly specialized team in performing intervention therapies for the treatment of potential complications, according to a Singapore study.
Treatment with sodium-glucose cotransporter-2 inhibitors (SGLT2i) results in a lower risk of clinically relevant cardiovascular death, heart failure (HF) hospitalization, and HF symptoms with similar rates of adverse events (AEs), results of a meta-analysis have shown.
DAV132, a novel, first-in-class, colon-targeted adsorbent capable of adsorbing a wide range of antibiotics, was well-tolerated in hospitalized elderly patients receiving oral/parenteral fluoroquinolones* (FQs), and protected the intestinal microbiota without influencing the plasma concentration of free FQs, the phase II European SHIELD trial has shown.
Heart failure (HF) is a global public health concern, affecting about 38 million individuals globally.1 Despite significant medical advances, HF remains a chronic and progressive condition that can negatively affect patients’ quality of life (QoL).2,3 In this case study, Dr Abdul Muizz shares his clinical experience in managing a patient with HF and reduced ejection fraction (HFrEF), following the percutaneous coronary intervention, showing how the initiation of sacubitril/valsartan therapy (an angiotensin receptor/neprilysin inhibitor [ARNI]) changed the clinical outcome of this patient.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).